[ Editorials - Sneak Previews - Update Briefs - Important Strategies - Dow 30 Market Timing - Kenneth Coleman ]
|
200 types of specialty coffees from over 18 different countries worldwide. It is one of the few places coffee drinkers can find Jamaican Blue Coffee. It recently added AnythingBOOKS.com. Call CEO J. Scott Sitra @ 719-227-1903 Ext. 102, fax 719-227-1907, e-mail: ssitra@anythingpc.com, or write 3020 North El Paso Rd., Suite 103, Colorado Springs, CO 80907. www.anythinginternet.com [R-7; M-7; L-8+] Channell Commercial Corporation (NASDAQ/CHNL) designs, manufactures & sells telecommunications equipment. Products include thermoplastic & metal fabricated enclosures, fiber optic cable management systems, coaxial-based passive RF electronics, & advanced copper termination & connecting components. Facilities are in CA, NC, Toronto, Kent (UK), & Sydney (Australia). CHNL sells to such cable & telephone companies as Bell Atlantic, BellSouth, GTE, Rogers-Canada, TCI, Telecom New Zealand, Time Warner, Vision Stream-Australia (Telestra), & such OEMs as AMP, DSC, Next Level, & Siecor. The "curb to the home" segment served by CHNL is about $500 million, growing about 8%/year Revenues & earnings have increased every year since 1993.
Revenues for Q2 (6/30/99) were $ 31.3 million, up 36%, with net
income $2.7 million, up from $2.3 million. Current assets at 6/30/99
were $41.1 million, current liabilities were $18.4 million, &
shareholders' equity was $57 million ($6.27 per share). CENI has been in business since 1902 & has consistently paid dividends. For Q2 (6/30/99), operating revenues were $17,880,000 & net income $1,486,000 ($0.19 per share). During Q2, Conestoga Wireless Co. added 2,500 subscribers, an increase of 73%. Conestoga Communications Co. increased its long distance |
service customers to over 21,000, adding about 5,000 new customers, & doubled its CLEC (Competitive Local Exchange) lines to over 2,800 lines in neighboring Bell & PA territories. CTT & BVT increased their access lines in service by 1,710 during Q1 & Q2. They had operating revenue growth of $1.7 million. Call Donald R. Breitenstein, controller @ 610-582-6226, fax 610-582-6338, e-mail dbreiten@ceni.com, or write CENI @ 202 East First Street, Birdsboro, PA 19508. www.ceni.com [R-7; M-6; L-7] ID Biomedical Corporation (NASDAQ/IDBE) is about to rapidly move from R&D to positive cash flow. It acquires important new technologies & products, demonstrates their clinical value through advanced R&D, & partners with senior companies to commercialize them. This strategy allows IDBE to realize faster near-term revenues, get external R&D funding, reduce development risk, & realize earnings earlier than companies that try to do the entire process themselves. IDBE is emerging in two medical product areas: vaccines, & rapid gene-based disease detection. It got the go-ahead from the FDA 6/9/99 to proceed with human clinical testing of a vaccine against group A streptococcus, which causes "strep throat," rheumatic fever, & "flesh eating disease." A therapeutic vaccine against AIDS is being developed in collaboration with professor Arye Rubenstein at the Albert Einstein College Of Medicine in NY. Small-scale human testing has been accomplished, & expanded human clinical trials are expected shortly. A vaccine for the prevention of TB, IDBE's TB vaccine, has been licensed to Pasteur Merieux Connaught, member of Aventis (formerly Hoechst/Rhone-Poulenc), & is in clinical development. The opportunity that will quickly move the company to commercialization is its VelogeneTM Rapid MRSA Identification Assay. It identifies antibiotic resistant Staphylococcus aureus (MRSA), one of the hospital "superbugs." It received FDA marketing approval 6/13/99 & is about to make its market launch in North America. After initial culture, this test will detect MRSA in about one hour, whereas current tests take one to two days. It identifies the mecA gene responsible for methicillin antibiotic resistance. In a trial at four hospitals, it correctly identified 99.3% of samples when compared to conventional susceptibility tests, & 100% when compared to Polymerase Chain Reaction, the current gold standard gene identification technology. Alexon-Trend, Inc. & other subsidiary companies of Sybron International Corp. (NYSE/SYB) will manufacture, market, & distribute this test, & IDBE's VRE test in all countries outside of Japan (IDBE is negotiating Japanese rights with several companies). Its VelogeneTM Rapid VRE Assay identifies antibiotic resistant enterococcus, another hospital "superbug," expected to be on the ...continued on next page, click here |
|
|
|
Disclaimer: The public companies featured in the Corporate Profiles listed in the "Special Situation" section on the Home Page of www.WallStreetCorner.com are our regular clients. Each such client pays an annual cash fee of $12,000, or alternatively, a monthly cash fee of $495 plus a negotiated number of Form 144 restricted shares for our service. We on rare occasions accept free-trading shares, but we usually hold such shares for the long pull - we do not engage in trading. Such fees are disclosed as part of the Corporate Profile prepared and posted on the particular company involved. The basic coverage provided to such clients primarily includes the preparation of their Corporate Profile, posting it here at WallStreetCorner.com, and the distribution of email alerts to our international database of investors and financial professionals when their Profile is initially posted, and each time their Profile is subsequently updated. We expect our clients to work with us in a team effort by calling us each time they have achieved a significant milestone. We then update their Profile and issue an additional email alert to our totally opt-in email database (as of July 2008, members of that database are from over 96 countries). The email distributions we make are a key element of our service -- those, as well as the updated Corporate Profile are what together are designed to achieve a gradual buildup of new shareholders who generally hold for the long term. If you are an officer at a public company and want the exposure afforded at WallStreetCorner.com, email Larry at up415@aol.com or call him at 843-645-2729. Information displayed by WallStreetCorner in its Corporate Profiles, and in its editorial or other columns, does not constitute an offer to buy, sell, or trade a security of any kind, including stock. Larry Oakley, and/or WallStreetCorner.com, Inc., does not recommend that any person, institution, or other entity make any decisions or form any opinions, etc. based on the information on this site. All visitors to this site are urged to do two things before investing in any stock: (1) Call the company and ask questions -- if there is anything you do not like regarding such call, pass -- our goal is to bring you a selection of what we feel are growth situations with good long-term appreciation potential, but you must accept the responsibility of making your own decisions regarding which situations to invest in -- do not give up that responsibility; and (2) Consult a qualified financial professional before taking any actions in regards to buying, selling, or trading securities (stocks or other forms of equity). Companies covered in Conservative Speculator, a newsletter accessed from WallStreetCorner, or in any of Larry Oakley's other editorial venues ("Opinion," "Stock Pick," "Comment," and "Bold Ventures" columns, and in any other editorial venue to which Larry contributes) do not pay for such editorial coverage; the companies Larry covers editorially have never, do not now, and never will be charged for editorial coverage. The only paid portions of WallStreetCorner.com are the Profiles and email distributions (email distributions are a part of the client's package, but occasionally are paid for separately by non-clients - if a non-client wants to utilize our email distributions, the cost is $2,000 for the first distribution, $1,500 for the second, $1,000 for the third, and $500 for all subsequent distributions made for the same company). On occasion, Larry Oakley shares his opinion regarding a private company or its product or service. Bear in mind that nothing at that special section is an investment possibility. To see that section, click where on the home page it says: "Click here to access our Special Emerging Growth Situations." See the introductory portion of that special section for additional information regarding the material covered there. |
|
|
WallStreetCorner.com |
